The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease.
Globally our industry is researching and developing more than 7,000 new medicines.
The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.
Notes to editors
NHS Scotland has made use of the PPRS payments being made by industry to create a fund to be spent on new medicines approved by the Scottish Medicines Consortium (SMC). The recently published. Montgomery Review has made recommendations to further improve access to medicines in Scotland and has been rapidly endorsed by Scottish Government to be taken forward. These two very positive measures which are unique to Scotland can be expected to help further improve access to medicines north of the border.
The Welsh Government has recently reduced the time taken to provide funding for NICE approved medicines from 90 days to 30 days and this can be expected to have a very positive impact on patient access to new medicines in Wales.